logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Ischemic Attack Transient

    Medications for Ischemic Attack Transient

    FiltersReset Filters
    3 results

    • ticagrelor

      (TICAGRELOR)
      Novadoz Pharmaceuticals LLC
      Usage: Ticagrelor is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It's also used in patients with coronary artery disease at high risk for first MI or stroke, and those with acute ischemic stroke or high-risk TIA.

    • ticagrelor

      (ticagrelor)
      Amneal Pharmaceuticals NY LLC
      Usage: Ticagrelor tablets are indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. They also prevent stent thrombosis and reduce the risk of first myocardial infarction or stroke in high-risk coronary artery disease patients.

    • ticagrelor

      (TICAGRELOR)
      AvKARE
      Usage: Ticagrelor tablets are indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also helps prevent first myocardial infarctions or strokes in high-risk patients with coronary artery disease and reduces stroke risk in acute ischemic stroke or high-risk TIA patients.